Quick takeaways
- Most common cagrilintide side effects are gastrointestinal: nausea, vomiting, constipation/diarrhoea, abdominal pain, reflux, and decreased appetite—especially during early dose escalation.
- Serious warning signs: severe abdominal pain (possible pancreatitis), right‑upper abdominal pain with fever or jaundice (possible gallbladder issue), dehydration, allergic reaction, or severe low blood sugar in people on diabetes medicines.
- Risk rises with faster titration and when combined with GLP‑1 medicines; slower increases and food/behavioural strategies often help.
- Not suitable for everyone: avoid in pregnancy/breastfeeding, severe gastroparesis, history of pancreatitis, or active gallbladder disease unless advised by a specialist.
Why cagrilintide causes these side effects
Cagrilintide mimics amylin, a hormone co‑secreted with insulin that promotes satiety and slows gastric emptying. This can reduce hunger and meal size—but the same mechanisms explain common side effects:
- Slower stomach emptying increases the chance of nausea, fullness, reflux and vomiting.
- Reduced intake and fluid shifts can contribute to constipation, dizziness and fatigue.
- When combined with GLP‑1 medicines, GI effects may add up, especially early on.
Common cagrilintide side effects
Reported in early‑ to mid‑stage clinical studies of cagrilintide (alone or with GLP‑1s):
- Nausea, vomiting
- Constipation or diarrhoea
- Abdominal discomfort or pain, bloating, indigestion
- Reduced appetite (intended effect but can be excessive)
- Reflux, burping
- Headache, dizziness, fatigue
- Injection‑site redness, itch, or tenderness
These effects are usually mild to moderate and tend to lessen over time, particularly with slower titration. If symptoms are severe, persistent, or interfere with hydration and nutrition, seek medical advice.
Serious risks and warning signs
Serious events are less common but require urgent medical assessment. Seek immediate care if you notice:
- Severe, persistent upper abdominal pain that may radiate to the back (with or without vomiting)—possible pancreatitis.
- Sudden right‑upper abdominal pain, fever, nausea/vomiting, yellowing of the skin/eyes—possible gallbladder or bile duct issue.
- Signs of dehydration or acute kidney stress: very dark urine, reduced urination, dizziness, fainting, confusion.
- Allergic reaction: widespread rash, swelling of lips/tongue/throat, trouble breathing.
- In people using insulin or sulfonylureas: sweating, shakiness, confusion, or fainting—possible severe hypoglycaemia.
Who should avoid or use caution
- History of pancreatitis or severe gastroparesis.
- Active gallbladder disease or high gallstone risk.
- Significant eating disorders or unexplained weight loss.
- Pregnancy or breastfeeding (insufficient safety data—avoid).
- Children and adolescents (safety not established).
- Kidney issues, dehydration risk, or on diuretics—need careful monitoring.
- Using insulin or sulfonylureas—monitor for hypoglycaemia; may require dose review.
- Combining with GLP‑1 medicines—expect higher GI burden and consider slower titration.
How to reduce side‑effect risk
- Start low, go slow: follow a cautious titration schedule; avoid jumping doses rapidly.
- Meal strategy: smaller portions, eat slowly, limit very fatty or spicy foods during escalation.
- Hydration plan: aim for regular fluids; add electrolytes if vomiting/diarrhoea occurs.
- Timing: some tolerate injections better at times that avoid large/fatty meals.
- Medication review: ask your prescriber to coordinate with any GLP‑1 therapy, insulin, or sulfonylureas.
- Report early: if nausea or constipation is building, ask about supportive measures before it worsens.
How cagrilintide side effects compare
- Versus semaglutide: both commonly cause GI symptoms. GLP‑1s can add risks like gallbladder disease; combining with cagrilintide may increase GI load early on.
- Versus tirzepatide: similar GI profile overall; tirzepatide has GLP‑1/GIP effects. Combination strategies with cagrilintide are under study.
- Combination (e.g., cagrilintide + semaglutide/CagriSema): may produce greater appetite control and weight loss in trials, but GI effects often require careful titration and support.
Monitoring checklist (practical)
- Track symptoms weekly during dose changes (nausea, vomiting, bowel habits, reflux, appetite, hydration).
- Watch weight trends to avoid excessive or rapid loss; escalate care if intake becomes inadequate.
- If diabetic: monitor glucose more frequently during initiation/adjustments; discuss insulin/sulfonylurea dose with your prescriber.
- Know the emergency red flags listed above and plan where to seek urgent care.
Frequently asked questions
What are the most common cagrilintide side effects?
Gastrointestinal symptoms—nausea, vomiting, constipation/diarrhoea, abdominal pain, reflux, reduced appetite—plus headache, dizziness, fatigue, and injection‑site reactions.
What are serious red flags?
Severe upper abdominal pain (possible pancreatitis), right‑upper abdominal pain with fever/jaundice (possible gallbladder issue), dehydration/fainting, allergic reaction, or severe low blood sugar if using insulin or sulfonylureas.
How can I prevent or reduce nausea?
Use slower dose escalation, smaller meals, avoid very fatty meals at escalation times, maintain hydration, and ask your prescriber about supportive options if needed.
Does cagrilintide have the same thyroid warnings as GLP‑1s?
Cagrilintide is an amylin analogue, not a GLP‑1. GLP‑1 class warnings do not automatically apply; however, many people take cagrilintide with GLP‑1s, so prescribers consider all relevant class warnings and individual risk factors.
Is it safe to combine cagrilintide with semaglutide or tirzepatide?
Combinations are being studied and may increase GI burden. Only do so under medical supervision, with careful dose titration and monitoring.
When should I stop and seek help?
Stop and seek urgent care for the red flags above, or if you cannot maintain hydration/nutrition, or if symptoms worsen despite supportive measures.
Is cagrilintide available in Australia?
It remains investigational. See access and regulatory notes here: Is Cagrilintide Legal in Australia?
Important
This page is educational and does not replace personalised medical advice. Always speak with a qualified health professional about your situation, medicines, and side‑effect management. If you experience severe or concerning symptoms, seek urgent medical care.
Need help with cagrilintide side effects?
Send us your question and we’ll point you to evidence‑based resources and appropriate next steps. We are an independent information resource and do not sell medications.
Final takeaway
Cagrilintide’s most common side effects are gastrointestinal and tend to improve with slower titration and supportive strategies. Serious warning signs—such as severe abdominal pain, gallbladder symptoms, dehydration, allergy, or severe hypoglycaemia in those on diabetes medicines—require urgent assessment. Because cagrilintide remains investigational, use only under appropriate medical oversight.